NRI Secure Launches Japan's First "Blockchain Assessment" Service
NRI SecureTechnologies, Ltd. (President: Jun Odashima; hereinafter NRI Secure), a leading provider of information security solutions in Japan, has begun providing Japan’s first-ever*1 “Blockchain Assessment,” a security Assessment service designed for systems and services which use blockchain technology*2.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005012/en/
Overview of the "Blockchain Assessment" Service (Graphic: Business Wire)
As the blockchain technology has become more widespread, the presence of security-related vulnerabilities has also become increasingly apparent. In particular, with regard to smart contracts, *3 one of a constituent element of services using the blockchain, a cyberattack carried out on any vulnerable programs could lead to major threats or even to actual damage*4 by causing services to behave differently than originally intended.
In response to these issues, NRI Secure has systematized its accumulated knowledge and insights in the form of the “Blockchain Assessment” service. As its first step, NRI Secure will be launching the security assessment service for smart contracts. The service performs assessment from the dual perspectives of static analysis, which carefully analyzes a program, and dynamic analysis, which involves simulating a real attack, in order to identify vulnerabilities.
More assessment menus for other constituent elements of the blockchain will be added in the future. (2 to 4 in the overview diagram). This service is only available in English and Japanese.
NRI Secure continues to provide a variety of products and services for supporting companies and organizations in their information security measures, and to contribute to the creation of a safe information system environment and society on a global scale.
|*1||First-ever in Japan: This is the first security assessment service designed specifically for the blockchain to be provided by a medium- or large-scale security vendor in Japan (according to NRI Secure research).|
|*2||Blockchain technology: A technology which achieves a distributed consensus among its participants and makes it possible to manage audit trails for all transactions, without the intervention of a trusted third party. Given such features as its ability to make falsifying data extremely difficult, its near-zero downtime, its lack of a centralized manager, and its high transaction performance, the blockchain has been lauded for being inexpensive to develop and for its potentially broad application as a way for companies to exchange information. These features have led to expectations that the blockchain can be used not only for cryptocurrencies such as Bitcoin, but as a circulation platform for transactions involving various asset types. Furthermore, this technology is also gaining notice for its potential use in the recording and storage of more common types of contracts, as well as in automatic contract execution.|
|*3||Smart contracts: This refers to contracts which are programmed and can be automatically executed. A smart contract is arranged with the execution conditions and contractual terms prescribed in advance, such that the contract is automatically executed when a transaction occurs matching said conditions. Smart contracts are being considered for use in securities settlements, real property transactions, the sharing economy, and numerous other fields that involve contracts.|
|*4||Actual damage: “The DAO Incident” occurred on June 17, 2016. Funds (virtual currency) held by “The DAO,” a virtual corporation established by a Germany-based venture capital company, were transmitted to a cyber-attacker who had exploited vulnerabilities in The DAO’s smart contract programming code.|
|*5||DApps: This abbreviation stands for Decentralized Applications, and refers to applications that are decentralized and distributed. They are said to enable the use of highly-reliably, low-cost applications via blockchain technology, without the need for a centralized system manager.|
About NRI Secure
NRI SecureTechnologies is a subsidiary of Nomura Research Institute
(NRI) specializing in Cybersecurity, and a leading global provider of
next-generation managed security services and security consulting.
Established in 2000, NRI SecureTechnologies is focused on delivering
high-value security outcomes for our clients with the precision and
efficiency that define Japanese quality.
For more details, visit us at http://www.nri-secure.com
“Blockchain Assessment” Service
Supported platforms: Ethereum, Hyperledger Fabric
*Additional platforms will be supported at a later time.
Supported languages: Solidity, Go, Java
*Please contact us regarding any other languages.
- Price: Estimates will be provided on an individual basis.
- For more details on the “Blockchain Assessment” Service, please contact: firstname.lastname@example.org.
NRI SecureTechnologies, Ltd.
Hitomi Nemoto, +81-3-6706-0622
NRI SecureTechnologies, Ltd.
Teruhiro Tagomori / Takenori Kiuchi, +81-3-6706-0622
Cyber Security Services Department II
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i